About Puma Biotechnology (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NYSE:PBYI
- CUSIP: N/A
- Web: www.pumabiotechnology.com/
- Market Cap: $4.64 billion
- Outstanding Shares: 37,205,000
- 50 Day Moving Avg: $112.81
- 200 Day Moving Avg: $79.93
- 52 Week Range: $28.35 - $127.02
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -26.58
- P/E Growth: 0.03
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.24 per share
- Price / Book: 38.47
- EBITDA: ($289,010,000.00)
- Return on Equity: -217.17%
- Return on Assets: -160.32%
- Current Ratio: 3.12%
- Quick Ratio: 3.12%
- Average Volume: 818,798 shs.
- Beta: 0.35
- Short Ratio: 6.75
Frequently Asked Questions for Puma Biotechnology (NYSE:PBYI)
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NYSE:PBYI) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.78. View Puma Biotechnology's Earnings History.
When will Puma Biotechnology make its next earnings announcement?
Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?
9 equities research analysts have issued 12-month target prices for Puma Biotechnology's shares. Their forecasts range from $88.00 to $156.00. On average, they anticipate Puma Biotechnology's share price to reach $124.89 in the next year. View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Ligand Pharmaceuticals Incorporated (LGND).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer
- Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer
- Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer
- Steven Lo, Chief Commercial Officer
- Jay M. Moyes, Independent Director
- Adrian M. Senderowicz M.D., Independent Director
- Troy E. Wilson Ph.D. J.D., Independent Director
- Frank E. Zavrl, Independent Director
Who owns Puma Biotechnology stock?
Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.04%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?
How do I buy Puma Biotechnology stock?
Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
MarketBeat Community Rating for Puma Biotechnology (NYSE PBYI)MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Puma Biotechnology stock can currently be purchased for approximately $124.65.
Consensus Ratings for Puma Biotechnology (NYSE:PBYI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 8 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.89)|
|Consensus Price Target: ||$124.89 (0.19% upside)|Consensus Price Target History for Puma Biotechnology (NYSE:PBYI)
Analysts' Ratings History for Puma Biotechnology (NYSE:PBYI)
(Data available from 10/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/9/2017||Bank of America Corporation||Reiterated Rating||Buy||$117.00 -> $135.00||N/A|
|10/5/2017||Citigroup Inc.||Reiterated Rating||Buy||$114.00 -> $156.00||N/A|
|10/4/2017||J P Morgan Chase & Co||Reiterated Rating||Buy||$131.00||High|
|10/2/2017||Stifel Nicolaus||Boost Price Target||Buy||$110.00 -> $130.00||Low|
|9/27/2017||Credit Suisse Group||Reiterated Rating||Outperform||$136.00||High|
|9/6/2017||Barclays PLC||Initiated Coverage||Overweight||$103.00||High|
|8/2/2017||Leerink Swann||Reiterated Rating||Outperform||$125.00||Low|
|7/22/2017||Cowen and Company||Reiterated Rating||Outperform||$91.00 -> $120.00||Medium|
|7/17/2017||Royal Bank Of Canada||Set Price Target||Hold||$88.00||Medium|
|1/5/2016||Berenberg Bank||Upgrade||Hold -> Buy||N/A|
Earnings History for Puma Biotechnology (NYSE:PBYI)Earnings History by Quarter for Puma Biotechnology (NYSE PBYI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Puma Biotechnology (NYSE:PBYI)
Current Year EPS Consensus Estimate: $-8.69 EPS
Next Year EPS Consensus Estimate: $-4.69 EPS
Dividend History for Puma Biotechnology (NYSE:PBYI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Puma Biotechnology (NYSE:PBYI)
Insider Ownership Percentage: 22.70%Insider Trades by Quarter for Puma Biotechnology (NYSE:PBYI)
Institutional Ownership Percentage: 80.98%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/29/2017||Richard Paul Bryce||SVP||Sell||15,000||$120.00||$1,800,000.00|| |
|9/7/2017||Richard Paul Bryce||SVP||Sell||15,000||$100.09||$1,501,350.00|| |
|7/20/2017||Alan H Auerbach||Insider||Sell||13,175||$94.73||$1,248,067.75|| |
|7/20/2017||Richard Paul Bryce||SVP||Sell||1,998||$94.48||$188,771.04|| |
|7/3/2017||Richard Paul Bryce||SVP||Sell||5,000||$87.10||$435,500.00|| |
|6/12/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||247,260||$80.32||$19,859,923.20|| |
|6/5/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||507,128||$87.84||$44,546,123.52|| |
|5/26/2017||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||1,235,700||$75.38||$93,147,066.00|| |
|2/1/2017||Robert Charnas||Insider||Sell||3,008||$31.83||$95,744.64|| |
|1/20/2017||Alan H Auerbach||Insider||Sell||10,202||$33.24||$339,114.48|| |
|1/20/2017||Richard Paul Bryce||SVP||Sell||2,293||$33.24||$76,219.32|| |
|7/6/2015||Richard Paul Bryce||SVP||Sell||3,000||$110.03||$330,090.00|| |
|11/8/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||22,549||$38.92||$877,607.08|| |
|11/5/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||280,700||$39.60||$11,115,720.00|| |
|10/9/2013||Adage Capital Partners Gp Llc||major shareholder||Buy||140,900||$40.44||$5,697,996.00|| |
|12/18/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||29,560||$19.00||$561,640.00|| |
|12/12/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||30,400||$19.00||$577,600.00|| |
|12/11/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||140,040||$18.98||$2,657,959.20|| |
|10/24/2012||Thomas Malley||Director||Buy||10,000||$16.00||$160,000.00|| |
|10/18/2012||Adage Capital Partners Gp Llc||Major Shareholder||Buy||610,000||$16.00||$9,760,000.00|| |
Headline Trends for Puma Biotechnology (NYSE:PBYI)
Latest Headlines for Puma Biotechnology (NYSE:PBYI)
Loading headlines, please wait.
Puma Biotechnology (PBYI) Chart for Saturday, October, 21, 2017